For global pharmaceutical companies, CTAs are the backbone of pharmaceutical innovation, governing relationships between sponsors, trial sites, vendors, and regulators. In addition to their volume growth, they are notoriously complex, often spanning multiple jurisdictions and requiring alignment with stringent regulatory frameworks. They are high-stakes contracts that require precision, compliance with ever-evolving regulations, and efficient execution across multiple jurisdictions. Traditional manual processes can slow trial initiation, delay drug development, and increase compliance risks.
The urgency has only grown. The Association of Clinical Research Professionals estimates that nearly half of all study delays are tied to the contracting and budgeting process— making CTA inefficiency one of the most costly bottlenecks in drug development. Industry analysts now project that AI-driven improvements could reduce development timelines for trials by at least six months, with 2026 marking a turning point as the industry moves from exploration to execution.
GenAI offers a way forward. It provides a transformative opportunity to reimagine CTA management by combining automation, analytics, and legal oversight. Specifically, it provides the potential to streamline contract drafting, automate compliance checks, and accelerate negotiation cycles, while also reducing risks of delays that can stall clinical trials and drug development.
This article explores how genAI can be strategically deployed by general counsel, legal operations teams, and contract lawyers to enhance the lifecycle of CTAs. Key article themes include:
- Operational efficiency: How genAI tools automate repetitive tasks such as clause generation, regulatory submissions, and more.
- Compliance and risk management: What can be implemented via AI to embed regulatory requirements directly into workflows.
- Legal and ethical considerations: How legal teams can address confidentiality, data protection, and ethical obligations.
- Regulatory alignment: With agencies like the FDA beginning to integrate GenAI into review processes, pharmaceutical companies must adapt their contracting practices to align with regulators’ expectations for transparency and data-driven operations.
Main Applications of GenAI for CTAs
The three main approaches in which genAI can be applied to reduce the time, cost, and effort of arriving at agreed to CTAs are the following:
Automated Drafting and Clause Generation
GenAI can streamline CTA work by automating drafting, which will help accelerate negotiations. Specifically, it can generate initial CTA drafts using pre-approved templates and clause libraries, reducing manual effort, and ensuring consistency across thousands of agreements.
It can also create dynamic clause adaption, by tailoring indemnity, confidentiality, and data sharing clauses to reflect jurisdiction-specific regulations such as GDPR in Europe, or HIPPA in the U.S. When it comes to counterparties rejecting standard terms, genAI can propose alternative “fallback language” clauses aligned with company policy, helping to avoid bottlenecks and speeding up negotiations.
Compliance and Risk Management
In addition to creating CTA process efficiencies, genAI can help with risk flagging, reducing cycle times, and freeing legal teams to focus on strategic oversight. Compliance automation via genAI can embed regulatory rules flag risks and adapt agreements to local laws and monitor compliance in real time.
These advancements can help ensure adherence to global and individual jurisdiction standards, e., US Food and Drug Administration (FDA), European Medicines Agency (EMA), Good Clinical Practice (GCP) directly into workflows, ensuring adherence to global standards and mitigating risks of non-compliance.
Analytics
GenAI supports analytics in CTAs in the following ways:
- Data extraction & structuring: It transforms unstructured legal text into structured datasets, enabling faster comparison of agreements across sites, sponsors, or CROs. Furthermore, key metrics (e.g., timelines, budget allocations, risk-sharing terms) can be extracted for dashboards and analytics.
- Risk & compliance insights: GenAI can flag potential risks (e.g., ambiguous liability clauses, non-standard regulatory language) and suggest standardized language to improve compliance. Likewise, it helps ensure agreements align with FDA, EMA, and ICH guidelines.
- Predictive analytics: GenAI can analyze historical agreements and trial outcomes to predict negotiation bottlenecks or identify which contract terms correlate with faster approvals. As a result, sponsors, and chief revenue officers (CROs) gain foresight into which terms drive efficiency or risk.
Key Governance and Oversight Considerations for Use of GenAI for CTAs
There are some legal and compliance considerations when it comes to genAI use. Organizational guidelines are required for confidentiality and data protection: HIPAA and GDPR compliance is critical, and safeguards for sensitive data need to be put in place. Guardrails against hallucinations, inaccuracies, and bias are essential, as is maintaining a log of AI inputs and outputs to ensure defensibility in regulatory reviews.
In a landmark development, the FDA and the EMA jointly identified ten guiding principles for good AI practice across the medicines lifecycle in January 2026, marking a significant step toward regulatory alignment on the use of advanced technologies in drug development. The principles cover evidence generation and monitoring spanning early research, clinical trials, manufacturing, and post-market safety surveillance, and are intended to inform sponsors, marketing authorization applicants, and authorization holders, while laying the foundation for future AI-specific guidance in both jurisdictions.
For CTA practitioners, this convergence matters. Sponsors must clearly specify how AI models will be used in drug development, identify potential risks and impacts to the study, quantify those risks, and have a plan to address them by evaluating the model under defined conditions. These requirements will increasingly filter into the representations, warranties, and compliance obligations embedded in CTAs themselves — particularly in agreements with CROs and site vendors who are deploying AI tools in trial execution.
Moreover, in the U.S., the American Bar Association (ABA) guidance requires human oversight of AI outputs; lawyers remain accountable. Through working with our clients, primarily large global enterprises, we have seen legal team roles and responsibilities play out as follows when it comes to applying genAI to CTAs, and contracts broadly speaking:
- General Counsel: Establishes policy, defines risk boundaries, and ensures accountability.
- Legal Operations: Designs workflows, monitors performance, and drives continuous improvement.
- Procurement Leaders: Align vendor contracts with AI-enabled standards and manage third-party risks.
- Contract Lawyers: Provide human-in-the-loop review, apply professional judgment, and adapt to evolving AI tools.
- Governance Tools: Audit trails, ethics boards, and proactive regulatory engagement strengthen oversight.
Future Outlook for GenAI Applied to CTAs
With agencies like the FDA beginning to integrate GenAI into review processes, pharmaceutical companies must adapt their contracting practices to align with regulators’ expectations for transparency and data-driven operations.
Expected changes include:
- Regulatory Evolution: FDA pilots and EMA initiatives will shape AI adoption in CTAs.
- Smart Contracts & Blockchain: Immutable, automated enforcement of trial obligations may become standard.
- Advanced Analytics: Predictive insights will forecast disputes, delays, and compliance risks.
- Shifting Legal Roles: Counsel will move from reactive contract management to proactive strategic oversight, with lawyers serving as ethical guardians of AI use.
Ultimately, genAI-managed CTAs represent a strategic inflection point for corporate legal teams in pharma: moving beyond administrative efficiency to become a driver of innovation, compliance, and competitive advantage in clinical development. By adopting genAI responsibly, legal leaders can position their organizations to accelerate trial timelines, safeguard sensitive data, and support faster patient access to life-saving therapies.
lntegreon
About the author
Domingo Senise de Gracia is Senior Vice President, Contracts & Compliance AI Solutions at Integreon and is based in Geneva, Switzerland. He has 25 years of experience in corporate strategy, innovation, and AI. Prior to Integreon, Domingo led global deployment of genAI for Contract Lifecycle Management at PwC. He is a frequent speaker at industry events on AI, with past engagements at venues including the World Economic Forum in Davos.
